Turning Point

Deloitte Report: Inaction on Climate Change Could Cost the US Economy $14.5 Trillion by 2070

Retrieved on: 
Tuesday, January 25, 2022
Sustainability, Climate, Consumer, Technology, Fortune 500, Turning Point, Acceleration, Industry, Multimedia, Climate change, GDP, Policy, Investment, Renewable energy, Accounting, Deloitte

Deloitte's analysis shows that insufficient action on climate change could cost the U.S. economy $14.5 trillion in the next 50 years.

Key Points: 
  • Deloitte's analysis shows that insufficient action on climate change could cost the U.S. economy $14.5 trillion in the next 50 years.
  • A loss of this scale is equivalent to nearly 4% of GDP or $1.5 trillion in 2070 alone.
  • And over the next 50 years, nearly 900,000 jobs could disappear each year due to climate damage.
  • This study is part of a series of Deloitte reports that examine the economic impact of climate change in regions including Europe and Asia Pacific.

Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, January 20, 2022
Patient, SAN, EML4-ALK positive lung cancer, MET, Private Securities Litigation Reform Act, SEC, Form 10-Q, Large-cell lung carcinoma, COVID-19, Safety, NASDAQ, GLOBE, TRK, ALK, IND, U.S. Securities and Exchange Commission, Turning Point, Therapy, ROS1, EGFR, NSCLC, SRC, Cancer, FDA, Investigational New Drug, Trial of the century, Pharmaceutical industry, CSF1R

Aumolertinib is EQRxs third generation EGFR inhibitor which is approved in China for first line treatment of EGFR mutant NSCLC and second line treatment of T790M+ EGFR mutant NSCLC.

Key Points: 
  • Aumolertinib is EQRxs third generation EGFR inhibitor which is approved in China for first line treatment of EGFR mutant NSCLC and second line treatment of T790M+ EGFR mutant NSCLC.
  • The combination of elzovantinib and aumolertinib will be studied in this Phase 1b/2 trial in patients with EGFR mutant MET-amplified advanced NSCLC who have progressed following treatment with osimertinib.
  • Preclinical data suggest the combination of MET and EGFR inhibition has the potential to increase anti-tumor activity based on complementary mechanisms.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones

Retrieved on: 
Tuesday, January 18, 2022
Patient, Research, SAN, EML4-ALK positive lung cancer, MET, Private Securities Litigation Reform Act, TKI, SEC, Form 10-Q, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Population, Safety, NASDAQ, CEO, GLOBE, ORR, TRK, IND, Leadership, Cancer, ALK, U.S. Securities and Exchange Commission, Turning Point, Therapy, Pharmacokinetics, ROS1, EGFR, DOR, NSCLC, SRC, Hand, Food, FDA, BID, KRAS, Large-cell lung carcinoma, PAK, Medicine, Pharmaceutical industry, CSF1R

As we look to 2022, we are focused on continuing progress across our clinical stage pipeline and expanding our discovery engine, said Athena Countouriotis, M.D., president and CEO.

Key Points: 
  • As we look to 2022, we are focused on continuing progress across our clinical stage pipeline and expanding our discovery engine, said Athena Countouriotis, M.D., president and CEO.
  • The company anticipates providing a clinical data update from the NTRK-positive advanced solid tumor cohorts from TRIDENT-1 in the second half of 2022.
  • The company anticipates providing a clinical data update from the Phase 1 SHIELD-1 study in the second half of 2022.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.

Turning Point Therapeutics Provides Regulatory Updates

Retrieved on: 
Monday, December 20, 2021
Therapy, Large-cell lung carcinoma, U.S. Securities and Exchange Commission, TRK, FDA, NDA, BID, Private Securities Litigation Reform Act, Lung cancer, SAN, TKI, COVID-19, Cancer, Time, SRC, NASDAQ, Review, SEC, Turning Point, Form 10-Q, Safety, Patient, MET, EML4-ALK positive lung cancer, GLOBE, Stomach, ROS1, ALK, Pharmaceutical industry, CSF1R

The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Key Points: 
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics drug candidates, repotrectinib and elzovantinib, plans regarding clinical trials, regulatory meetings and regulatory submissions, and the regulatory approval paths for repotrectinib and elzovantinib.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.
  • Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point Therapeutics business and the other risks described in Turning Point Therapeutics filings with theSEC, including its quarterly report on Form 10-Q filed with theSecurities and Exchange Commission (SEC)onNovember 9, 2021.

Huobi Research Institute Publishes Report on Fed Tapering and its Potential Effects on Cryptocurrency Markets

Retrieved on: 
Monday, December 6, 2021
Government, University, Fed, Research report, Cryptocurrency, Research, Blockchain, Turning Point, COVID-19

LONDON, Dec. 6, 2021 /PRNewswire/ --Huobi Research Institute, the leading blockchain application research team, has published its latest research report: Taper Landed: the Turning Point of The Cryptocurrency Market is Coming?

Key Points: 
  • LONDON, Dec. 6, 2021 /PRNewswire/ --Huobi Research Institute, the leading blockchain application research team, has published its latest research report: Taper Landed: the Turning Point of The Cryptocurrency Market is Coming?
  • The report discusses Fed tapering in the U.S. and its potential impact on cryptocurrency markets.
  • This report by Huobi Research Institute takes a look at the impact of tightening monetary policies in the U.S., and their potential impact on cryptocurrency markets.
  • Huobi Blockchain Application Research Institute (referred to as "Huobi Research Institute") was established in April 2016.

Circular economy presents significant opportunities and unique challenges for Canada: New report

Retrieved on: 
Thursday, November 25, 2021
FCAHS, Environment and Climate Change Canada, Royal, Perception, CEO, Environment, Turning Point, CE, Outline of health sciences, British Columbia Basic Income Expert Panel Report, CCA, Academy, Canadian Academy of Engineering, Doctor of Philosophy, Fellows, Education, Director, Biodiversity loss, Goal, Royal Society, Point, GLOBE, Council, Organization, Board, Tobacco Products Scientific Advisory Committee, Water, Â, Public policy, FRSC, Climate change, Canadian Academy of Health Sciences, Renewable energy, Recycling, Management

Only 6% of materials entering the economy come from recycled sources, while almost three-quarters of what we use is wasted.

Key Points: 
  • Only 6% of materials entering the economy come from recycled sources, while almost three-quarters of what we use is wasted.
  • According to a new expert panel report from the Council of Canadian Academies (CCA), Canada may be throwing away significant opportunities and potential wealth along with all that waste.
  • Only a small portion of materials are ever cycled back into the economy, resulting in a massive loss of value.
  • Environment and Climate Change Canada asked the CCA to examine the potential opportunities and challenges for a circular economy in Canada.

Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics

Retrieved on: 
Thursday, November 11, 2021
GMP, Rehabilitation Research and Development Service, Cancer, Therapy, EML4-ALK positive lung cancer, MET, DMPK, SAN, CIRC, Degenerative disease, Radiopharmaceutical, Pharmacology, ADME, II, TRK, API, CNS, Point, Lists of diseases, Choice, Turning Point, Company, ROS1, Toxicology, Large-cell lung carcinoma, Chemistry, Contract, PR, Contract research organization, Zenith Contract Services, Biology, JPL, Biosys, Patient, SRC, Jubilant, ALK, Pharmaceutical industry, Fine chemical

Services for Turning Point Therapeutics Inc. will be conducted out of Jubilant Biosys Limited's newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida, India.

Key Points: 
  • Services for Turning Point Therapeutics Inc. will be conducted out of Jubilant Biosys Limited's newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida, India.
  • It's Chemistry Innovation Research Center has an initial capacity of 500 FTEs enabling higher operational performance for discovery chemistry services and also rapid turn-around of in-vitro ADME data for client projects.
  • Jubilant Biosys Limited, a subsidiary of Jubilant Pharmova Limited, an integrated global pharmaceutical company, has presence in Bengaluru and Noida in India.
  • Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India.

Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics

Retrieved on: 
Thursday, November 11, 2021
GMP, Rehabilitation Research and Development Service, Cancer, Therapy, EML4-ALK positive lung cancer, MET, DMPK, SAN, CIRC, Degenerative disease, Radiopharmaceutical, Pharmacology, ADME, II, TRK, API, CNS, Point, Lists of diseases, Choice, Turning Point, Company, ROS1, Toxicology, Large-cell lung carcinoma, Chemistry, Contract, PR, Contract research organization, Zenith Contract Services, Biology, JPL, Biosys, Patient, SRC, Jubilant, ALK, Pharmaceutical industry, Fine chemical

Services for Turning Point Therapeutics Inc. will be conducted out of Jubilant Biosys Limited's newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida, India.

Key Points: 
  • Services for Turning Point Therapeutics Inc. will be conducted out of Jubilant Biosys Limited's newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida, India.
  • It's Chemistry Innovation Research Center has an initial capacity of 500 FTEs enabling higher operational performance for discovery chemistry services and also rapid turn-around of in-vitro ADME data for client projects.
  • Jubilant Biosys Limited, a subsidiary of Jubilant Pharmova Limited, an integrated global pharmaceutical company, has presence in Bengaluru and Noida in India.
  • Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India.

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 10, 2021
Cancer, Private Securities Litigation Reform Act, Therapy, Investor, MET, SAN, NASDAQ, COVID-19, TRK, Evercore, Turning Point, Conference, GLOBE, ROS1, Large-cell lung carcinoma, U.S. Securities and Exchange Commission, SEC, Webcast, SRC, Form 10-Q, Patient, ALK, EML4-ALK positive lung cancer, Pharmaceutical industry

ET (12:20 p.m. GMT) on November 16 and participate in a virtual fireside chat at 1 p.m.

Key Points: 
  • ET (12:20 p.m. GMT) on November 16 and participate in a virtual fireside chat at 1 p.m.
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.

Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates

Retrieved on: 
Tuesday, November 9, 2021
Cancer, Therapy, Congress, Hand, Food, D, COVID-19, IMT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TKI, SRC, EML4-ALK positive lung cancer, China, Safety, SAN, BID, Dizziness, Research, GEJ, Intention, Conference, GLOBE, ROS1, Large-cell lung carcinoma, Patient, FDA, Adult, Data, Private Securities Litigation Reform Act, MET, NASDAQ, CEO, QD, Ryan Corr, TRK, U.S. Securities and Exchange Commission, SEC, Pharmacokinetics, Corr, ALK, SFM, CARE, Investment, EGFR, AACR, ISO 20022, Turning Point, KRAS, BTD, Form 10-Q, IND, Pharmaceutical industry

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided operational updates.

Key Points: 
  • SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided operational updates.
  • Turning Point will webcast its Quarterly Update Conference Call today, November 9 at 4:30 p.m. ET/1:30 p.m. PT.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.